Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Fasching, P; Stradner, M; Graninger, W; Dejaco, C; Fessler, J.
Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders.
Molecules. 2017; 22(1):
Doi: 10.3390/molecules22010134
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Dejaco Christian
- Fasching Patrizia
- Co-Autor*innen der Med Uni Graz
- Fessler Johannes
- Graninger Winfried
- Stradner Martin Helmut
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- A disruption of the crucial balance between regulatory T-cells (Tregs) and Th17-cells was recently implicated in various autoimmune disorders. Tregs are responsible for the maintenance of self-tolerance, thus inhibiting autoimmunity, whereas pro-inflammatory Th17-cells contribute to the induction and propagation of inflammation. Distortion of the Th17/Treg balance favoring the pro-inflammatory Th17 side is hence suspected to contribute to exacerbation of autoimmune disorders. This review aims to summarize recent data and advances in targeted therapeutic modification of the Th17/Treg-balance, as well as information on the efficacy of candidate therapeutics with respect to the treatment of autoimmune diseases.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals -
- Antibodies, Monoclonal - therapeutic use
- Autoimmune Diseases - drug therapy
- Autoimmune Diseases - genetics
- Autoimmune Diseases - immunology
- Autoimmune Diseases - pathology
- Forkhead Transcription Factors - antagonists & inhibitors
- Forkhead Transcription Factors - genetics
- Forkhead Transcription Factors - immunology
- Gene Expression Regulation -
- Humans -
- Immunologic Factors - therapeutic use
- Inflammation -
- Interleukin-17 - antagonists & inhibitors
- Interleukin-17 - genetics
- Interleukin-17 - immunology
- Nuclear Receptor Subfamily 1, Group F, Member 3 - antagonists & inhibitors
- Nuclear Receptor Subfamily 1, Group F, Member 3 - genetics
- Nuclear Receptor Subfamily 1, Group F, Member 3 - immunology
- Piperidines - therapeutic use
- Pyrimidines - therapeutic use
- Pyrroles - therapeutic use
- Signal Transduction -
- T-Lymphocytes, Regulatory - drug effects
- T-Lymphocytes, Regulatory - immunology
- T-Lymphocytes, Regulatory - pathology
- Th17 Cells - drug effects
- Th17 Cells - immunology
- Th17 Cells - pathology
- Ustekinumab - therapeutic use
- Find related publications in this database (Keywords)
- Th17-cells
- regulatory T-cells
- autoimmunity
- RORt
- Foxp3